Below you’ll find all of our archived press releases, articles written by the Crohn's & Colitis Foundation, as well as research articles from external media sources. You can also search for a specific news item or topic by using direct keywords (for example, “the foundation research”) or by filtering the news by date or category.
Please note: If you are a member of the media interested in speaking with a foundation's spokesperson, contact us today.
Thank you to the Allergan Foundation for investing in Camp Oasis with a $5,000 grant! From Left to right: Bill Meury, Allergan Foundation board member and Executive VP, Chief Commercial Officer; Jonathon Kellerman, Allergan Foundation board member and Executive VP, Global Chief Compliance Officer; Denise Desmond, Crohn’s & Colitis Foundation Orange County Chapter, Executive Director, Gwyn Grenrock, Executive Director of The Allergan Foundation; and Alex Kelly, Allergan Foundation President and Executive VP, Chief Communications Officer.
Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Diseases (IBD) Receives FundingMay 17, 2018
Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel diseases (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.
Clinical trial recruitment is the biggest barrier to the development and approval of new treatments. In order to understand patient perceptions and improve recruitment, the Crohn’s & Colitis Foundation conducted in-person focus groups over a four-month period in 2016, the results of which are published in the paper "Crohn’s disease and ulcerative colitis patient perspectives on clinical trials and participation."
Leading Patient & Professional Organizations Announce Funding to Improve Communications & Address Shared Decision-making in Inflammatory Bowel DiseasesApril 17, 2018
The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.
The Crohn's & Colitis Foundation Selects Diversigen, Inc. as a Preferred Provider for Metagenomics and Microbiome Analysis ServicesApril 11, 2018
Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.
exploring the relationship between accutane and ulcerative colitis
Crohn’s & Colitis Awareness Week kicks off on December 1, and in recognition of the observance, New Orleans Saints linebacker Michael Mauti will dedicate his cleats during Week 13 of the NFL season to help raise awareness of these inflammatory bowel diseases (IBD) and the critical work of the Crohn’s & Colitis Foundation to find cures for Crohn’s disease and ulcerative colitis. Mauti’s cleat design features the Foundation’s logo along with the Colitis Ninja, an icon of ulcerative colitis blogger Amber Elder, who is local to Mauti’s home state of Louisiana.
Crohn’s & Colitis Foundation Receives $5 Million to Fund Innovative Translational and Clinical IBD ResearchOctober 30, 2017
The Crohn’s & Colitis Foundation announced that it received a $5 million pledge from the Litwin family to fund novel, high-risk/high-reward research ideas in the early stage of exploration that could advance the field of inflammatory bowel diseases (IBD) research.
The Crohn’s & Colitis Foundation (the Foundation) celebrates the visionary academic and industry scientists, The Leona M. and Harry B. Helmsley Charitable Trust, IBD patients, and Foundation staff who are partnering to create and sustain IBD Plexus®, a first-of-its-kind research information exchange platform designed to centralize data and biosamples from diverse research studies. The powerful new initiative is designed to advance our understanding of Crohn’s disease and ulcerative colitis, or inflammatory bowel diseases (IBD), and significantly accelerate research driving toward precision medicine and cures for IBD.
Leading Patient Organizations Collaborate to Improve Patient Care in IBD Through Shared Decision-MakingSeptember 11, 2017
The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA),in collaboration with Pfizer, Inc., announced today a request for proposal (RFP), around interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians. The goal is to identify and/or establish best practices around shared decision-making that can be easily replicated, broadly disseminated, and widely adopted within the IBD community.
The Crohn’s & Colitis Foundation released the following statement today after the New York State Senate passed the Crohn’s & Colitis Fairness Act (S3295).